Pandia Health’s hormone catalog puts Progesterone and Prometrium beneath a capsule heading. That is more specific than a general promise to provide hormone care, but the two entries do not answer every question in the same way. A brand name can point to a particular label; a broader ingredient entry still needs a selected product.
This review, dated September 29, 2026, considers the catalog, care plans and official reference labeling. It keeps the named product evidence separate from unverified stock or an individual prescription. No consultation, transferred order, supplied capsule or pharmacy transaction was tested.
Read this article by section
The named brand provides a reference point, not an authenticated order
Pandia’s therapy catalog lists Prometrium alongside Progesterone in its capsule group. The official Prometrium label identifies a micronized oral progesterone formulation. That provides a product-specific reference for the brand name, without proving that any visitor will receive it from Pandia.
A catalog can describe an available pathway while leaving current inventory, the requested prescription and selected supply unresolved. The Prometrium review concerns the named medicine itself. Pandia’s review concerns the provider offering, which needs an additional connection between the catalog entry and an actual order before product labeling can be applied to what is dispensed. Even the branded entry cannot establish that every listed strength or package is available at the time an order is requested. Availability and clinical selection remain separate from the existence of a reference label.
The broader progesterone entry still needs its own identity
The same catalog also uses the ingredient name without identifying a manufacturer in the reviewed entry. FDA’s generic-drug facts explain the requirements for an approved generic, including strength, dosage form, administration route and bioequivalence. Those requirements are not established merely by displaying the ingredient name.
The micronized terminology guide makes the distinction between a descriptive word and the finished formulation. Once a particular generic is identified, its own product information can be considered. Until then, this review does not assign the brand’s complete label or inactive ingredients to every capsule grouped nearby, nor does it question an identified approved generic’s regulatory status.
Inactive ingredients are not a property of the catalog heading
The Prometrium label declares peanut oil and gelatin, with additional ingredients that vary between labeled strengths. These are facts about that product. They do not establish the ingredients of every capsule identified only as progesterone elsewhere on Pandia’s site.
An ingredient concern therefore needs the product and its current label, rather than a conclusion drawn from the capsule category. MyMenopauseRx’s assessment examines a provider’s discussion of manufacturer and pharmacy questions. Both comparisons leave personal allergy evaluation with the appropriate professionals. This publication cannot certify an alternative as suitable, infer an excipient list from a familiar hormone or verify a pharmacy’s actual supply.
Neighboring estrogen formats should not be assigned to progesterone
Pandia’s menu contains separate groups for estradiol tablets, vaginal creams, vaginal products and rings. Their proximity to the progesterone capsules does not make them progesterone formulations. The hormone and the administration form need to remain paired correctly when the menu is summarized.
The route guide considers why oral, vaginal and topical descriptions carry different evidence questions. Stella’s review shows another possible source of confusion: several products appearing within a sample care plan. Neither arrangement allows the reader to borrow a neighboring route or decide that a capsule can be used differently because another medicine is delivered that way.
A transferred prescription is different from a newly selected treatment
Pandia’s care page describes an existing-prescription transfer route as well as menopause care. Transferring an order and obtaining a clinical assessment are different services. The transfer does not independently establish why the original product was chosen or whether a change in formulation is appropriate.
The approval discussion supplies context for reading a product’s regulatory description once its identity is known. It does not turn a transfer into permission to replace one preparation with another. The useful handoff preserves the medicine’s actual name and intended use, while making clear which clinician and pharmacist can answer product, prescription and treatment questions.
The advertised plans exclude a complete medicine quote
Pandia’s published care plans show $69 monthly, $59 per month for a three-month option and $34.99 per month for an annual option totaling $419.88. The three-month total appears as “#177,” so this review retains the malformed display instead of presenting it as a verified charge. The savings wording also does not settle a selected checkout.
Medicines are charged separately. The page does not bill insurance for the consultation service, while pharmacy benefits may apply. Cancellation language includes thirty days’ notice before the next bill and a possible early fee. Those details matter when comparing a named capsule entry with the cost of the professional service needed to obtain a prescription.
A useful comparison stops where the product record stops
Pandia’s catalog and treatment explanation confirm relevant capsule entries and a clinical route. They do not prove a particular preparation’s stock, expected personal benefit or the outcome of a prescription transfer. Educational schedule examples on the page are not reproduced here as instructions.
The next questions concern the exact proposed product, its own label, the reason it has been selected and the full agreement covering care and supply. A branded entry offers a helpful starting reference, but the review does not extend its evidence to every nearby item. This distinction allows the catalog to remain useful without becoming a recommendation to choose a brand, change a medicine or infer suitability from a familiar name.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Pandia Health: menopause hormone therapyProvider therapy and capsule catalog; names progesterone and Prometrium, no selected stock or equivalence inference; public regimens not transferred · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsule label, updated July 23, 2026Official structured label for the named oral product; chemical identity, micronization, formulation-specific ingredients and indications, not evidence of a reviewed provider supplying it · Checked 2026-09-29
- FDA: Generic Drug FactsFederal generic-drug approval explanation; exact active ingredient, strength, dosage form, route and bioequivalence requirements, not a selected product or substitution instruction · Checked 2026-09-29
- Pandia Health: menopause care and deliveryDated provider plans and prescription-transfer offer; separate medicine cost, billing units, 30-day notice and possible early fee, malformed three-month currency and inconsistent savings retained · Checked 2026-09-28